Incyte Stock Performance
| INCY Stock | USD 100.75 1.91 1.93% |
The company retains a Market Volatility (i.e., Beta) of 1.04, which attests to a somewhat significant risk relative to the market. Incyte returns are very sensitive to returns on the market. As the market goes up or down, Incyte is expected to follow. At this point, Incyte has a negative expected return of -0.0266%. Please make sure to check out Incyte's total risk alpha, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Incyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Incyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Incyte is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.93 | Five Day Return (2.89) | Year To Date Return (0.66) | Ten Year Return 47.38 | All Time Return 5.3 K |
Last Split Factor 2:1 | Last Split Date 2000-09-01 |
1 | Disposition of 5233 shares by Stein Steven H of Incyte at 102.2 subject to Rule 16b-3 | 11/14/2025 |
2 | The Bull Case For Incyte Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan | 12/23/2025 |
3 | This Biotech Stock Eyes Fresh Entry With 522 percent Earnings Growth Seen | 01/09/2026 |
4 | Reassessing Incyte Valuation After Wells Fargos Neutral Downgrade | 01/21/2026 |
5 | CMS Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China | 01/30/2026 |
6 | Assessing Incyte Valuation After Strong 1 Year Return And Recent Share Price Cooldown | 02/02/2026 |
7 | Analysts Differ in Opinion on Jakafi Drug Maker Incyte | 02/03/2026 |
8 | TD Cowen Keeps Buy Rating on Incyte , Cites Roadmap to Triple Non-Jakafi Revenue by 2029 | 02/04/2026 |
9 | Incytes Zynyz Wins CHMP Backing And Opens New EU Opportunity | 02/06/2026 |
10 | Incyte Q4 Earnings What To Expect | 02/09/2026 |
11 | Incyte falls as Q4 results, 2026 revenue guidance disappoint | 02/10/2026 |
12 | Is It Too Late To Consider Incyte After Its 43 percent One Year Rally | 02/12/2026 |
| Begin Period Cash Flow | 1.7 B | |
| Total Cashflows From Investing Activities | -102.6 M |
Incyte Relative Risk vs. Return Landscape
If you would invest 10,417 in Incyte on November 15, 2025 and sell it today you would lose (342.00) from holding Incyte or give up 3.28% of portfolio value over 90 days. Incyte is currently does not generate positive expected returns and assumes 2.4224% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Incyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Incyte Target Price Odds to finish over Current Price
The tendency of Incyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 100.75 | 90 days | 100.75 | about 68.3 |
Based on a normal probability distribution, the odds of Incyte to move above the current price in 90 days from now is about 68.3 (This Incyte probability density function shows the probability of Incyte Stock to fall within a particular range of prices over 90 days) .
Incyte Price Density |
| Price |
Predictive Modules for Incyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Incyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Incyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Incyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Incyte is not an exception. The market had few large corrections towards the Incyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Incyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Incyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 1.04 | |
σ | Overall volatility | 3.55 | |
Ir | Information ratio | -0.06 |
Incyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Incyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Incyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Incyte generated a negative expected return over the last 90 days | |
| Incyte has a very strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Is It Too Late To Consider Incyte After Its 43 percent One Year Rally |
Incyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Incyte Stock often depends not only on the future outlook of the current and potential Incyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Incyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 200.7 M | |
| Cash And Short Term Investments | 3.6 B |
Incyte Fundamentals Growth
Incyte Stock prices reflect investors' perceptions of the future prospects and financial health of Incyte, and Incyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Incyte Stock performance.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 16.13 B | ||||
| Shares Outstanding | 199.01 M | ||||
| Price To Earning | 19.17 X | ||||
| Price To Book | 3.81 X | ||||
| Price To Sales | 3.83 X | ||||
| Revenue | 5.14 B | ||||
| Gross Profit | 4.77 B | ||||
| EBITDA | 1.76 B | ||||
| Net Income | 1.29 B | ||||
| Cash And Equivalents | 2.72 B | ||||
| Cash Per Share | 12.24 X | ||||
| Total Debt | 69.43 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.91 X | ||||
| Book Value Per Share | 26.17 X | ||||
| Cash Flow From Operations | 1.41 B | ||||
| Earnings Per Share | 6.41 X | ||||
| Market Capitalization | 19.67 B | ||||
| Total Asset | 6.96 B | ||||
| Retained Earnings | 213.77 M | ||||
| Working Capital | 3.51 B | ||||
| Current Asset | 842.38 M | ||||
| Current Liabilities | 168.01 M | ||||
About Incyte Performance
Evaluating Incyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Incyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Incyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 84.08 | 88.28 | |
| Return On Tangible Assets | 0.19 | 0.20 | |
| Return On Capital Employed | 0.25 | 0.26 | |
| Return On Assets | 0.18 | 0.19 | |
| Return On Equity | 0.25 | 0.18 |
Things to note about Incyte performance evaluation
Checking the ongoing alerts about Incyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Incyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Incyte generated a negative expected return over the last 90 days | |
| Incyte has a very strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Is It Too Late To Consider Incyte After Its 43 percent One Year Rally |
- Analyzing Incyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Incyte's stock is overvalued or undervalued compared to its peers.
- Examining Incyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Incyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Incyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Incyte's stock. These opinions can provide insight into Incyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.